Eli Lilly announced that its oral glucagon-like peptide-1 (GLP-1) receptor agonist Foundayo met the primary endpoint in late-stage studies of adults with obesity and moderate-to-severe obstructive sleep apnea. In the 712-patient program, reductions in sleep-related breathing interruptions reached up to 44% after 52 weeks among participants not using positive airway pressure (PAP), versus 27.5% among those using PAP, according to the reported results. The drug also produced weight loss and improvements in measures of oxygen deprivation during sleep. Lilly plans to seek U.S. approval for the new indication before the end of 2026.
Reuters
Source: Reuters, November 9
Why it matters strategically
The obesity pharmaceutical market is expanding from weight management toward treatment of obesity-associated diseases.
However, improvement in a sleep-apnea endpoint does not automatically establish that oral pharmacotherapy can replace PAP in all patients.
The commercial opportunity depends on patient selection, comparative treatment effectiveness, adherence, and reimbursement.
